Vitrolife AB (publ) (VITR.ST)
SEK 214.4
(1.13%)
SEK 214.4
(1.13%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.22 Billion SEK | -25.44% |
| 2022 | 1.64 Billion SEK | -11.09% |
| 2021 | 1.85 Billion SEK | 303.3% |
| 2020 | -911.16 Million SEK | -48.47% |
| 2019 | -613.69 Million SEK | -25.04% |
| 2018 | -490.81 Million SEK | -24.1% |
| 2017 | -395.48 Million SEK | -161.24% |
| 2016 | -151.38 Million SEK | 0.45% |
| 2015 | -152.06 Million SEK | -597.4% |
| 2014 | -21.8 Million SEK | -44.22% |
| 2013 | -15.11 Million SEK | -123.86% |
| 2012 | 63.37 Million SEK | 37.48% |
| 2011 | 46.09 Million SEK | 37.35% |
| 2010 | 33.56 Million SEK | 677.33% |
| 2009 | -5.81 Million SEK | 22.19% |
| 2008 | -7.47 Million SEK | 59.63% |
| 2007 | -18.5 Million SEK | -27.89% |
| 2006 | -14.47 Million SEK | 70.04% |
| 2005 | -48.29 Million SEK | -7.48% |
| 2004 | -44.93 Million SEK | 0.0% |
| 2003 | - SEK | 0.0% |
| 2002 | - SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.12 Billion SEK | -8.55% |
| 2024 Q3 | 995 Million SEK | -9.42% |
| 2024 Q2 | 1.24 Billion SEK | 10.6% |
| 2023 FY | 1.22 Billion SEK | -25.44% |
| 2023 Q4 | 1.22 Billion SEK | -10.89% |
| 2023 Q3 | 1.37 Billion SEK | -13.17% |
| 2023 Q2 | 1.58 Billion SEK | 3.25% |
| 2023 Q1 | 1.53 Billion SEK | -6.68% |
| 2022 Q1 | 1.87 Billion SEK | 1.17% |
| 2022 Q4 | 1.64 Billion SEK | -5.72% |
| 2022 FY | 1.64 Billion SEK | -11.09% |
| 2022 Q3 | 1.74 Billion SEK | -8.0% |
| 2022 Q2 | 1.89 Billion SEK | 1.33% |
| 2021 Q2 | -1.08 Billion SEK | -2.47% |
| 2021 FY | 1.85 Billion SEK | 303.3% |
| 2021 Q1 | -1.05 Billion SEK | -16.07% |
| 2021 Q4 | 1.85 Billion SEK | 139.45% |
| 2021 Q3 | -4.69 Billion SEK | -333.26% |
| 2020 Q1 | -640.78 Million SEK | -4.41% |
| 2020 Q4 | -911.16 Million SEK | -18.7% |
| 2020 FY | -911.16 Million SEK | -48.47% |
| 2020 Q2 | -682.75 Million SEK | -6.55% |
| 2020 Q3 | -767.63 Million SEK | -12.43% |
| 2019 Q2 | -367.23 Million SEK | 17.51% |
| 2019 Q1 | -445.2 Million SEK | 9.29% |
| 2019 FY | -613.69 Million SEK | -25.04% |
| 2019 Q4 | -613.69 Million SEK | -17.9% |
| 2019 Q3 | -520.49 Million SEK | -41.73% |
| 2018 Q1 | -398.8 Million SEK | -0.84% |
| 2018 Q2 | -421.39 Million SEK | -5.66% |
| 2018 Q3 | -496.22 Million SEK | -17.76% |
| 2018 Q4 | -490.81 Million SEK | 1.09% |
| 2018 FY | -490.81 Million SEK | -24.1% |
| 2017 FY | -395.48 Million SEK | -161.24% |
| 2017 Q4 | -395.48 Million SEK | -38.98% |
| 2017 Q3 | -284.56 Million SEK | -39.64% |
| 2017 Q2 | -203.78 Million SEK | -11.1% |
| 2017 Q1 | -183.42 Million SEK | -21.16% |
| 2016 Q1 | -157.32 Million SEK | -3.46% |
| 2016 Q4 | -151.38 Million SEK | -95.63% |
| 2016 Q3 | -77.38 Million SEK | -137.74% |
| 2016 Q2 | -32.55 Million SEK | 79.31% |
| 2016 FY | -151.38 Million SEK | 0.45% |
| 2015 Q1 | -16.76 Million SEK | 23.11% |
| 2015 Q4 | -152.06 Million SEK | -137.97% |
| 2015 Q3 | -63.9 Million SEK | -746.05% |
| 2015 Q2 | -7.55 Million SEK | 54.95% |
| 2015 FY | -152.06 Million SEK | -597.4% |
| 2014 Q3 | -91.87 Million SEK | -131.37% |
| 2014 Q4 | -21.8 Million SEK | 76.27% |
| 2014 Q2 | -39.7 Million SEK | -27.65% |
| 2014 Q1 | -31.1 Million SEK | -105.75% |
| 2014 FY | -21.8 Million SEK | -44.22% |
| 2013 Q4 | -15.11 Million SEK | -199.95% |
| 2013 Q2 | 46.25 Million SEK | -1.57% |
| 2013 Q1 | 46.99 Million SEK | -25.85% |
| 2013 Q3 | 15.12 Million SEK | -67.3% |
| 2013 FY | -15.11 Million SEK | -123.86% |
| 2012 Q1 | 36.65 Million SEK | -20.49% |
| 2012 Q4 | 63.37 Million SEK | -85.37% |
| 2012 FY | 63.37 Million SEK | 37.48% |
| 2012 Q2 | 47.25 Million SEK | 28.92% |
| 2012 Q3 | 433.24 Million SEK | 816.91% |
| 2011 Q3 | 54.34 Million SEK | -3.85% |
| 2011 Q1 | 44.07 Million SEK | 31.34% |
| 2011 Q2 | 56.51 Million SEK | 28.23% |
| 2011 FY | 46.09 Million SEK | 37.35% |
| 2011 Q4 | 46.09 Million SEK | -15.17% |
| 2010 FY | 33.56 Million SEK | 677.33% |
| 2010 Q4 | 33.56 Million SEK | 448.81% |
| 2010 Q3 | 6.11 Million SEK | 161.66% |
| 2010 Q2 | 2.33 Million SEK | 0.0% |
| 2009 Q4 | -5.81 Million SEK | 0.0% |
| 2009 FY | -5.81 Million SEK | 22.19% |
| 2008 FY | -7.47 Million SEK | 59.63% |
| 2007 FY | -18.5 Million SEK | -27.89% |
| 2006 FY | -14.47 Million SEK | 70.04% |
| 2005 FY | -48.29 Million SEK | -7.48% |
| 2004 FY | -44.93 Million SEK | 0.0% |
| 2003 FY | - SEK | 0.0% |
| 2002 FY | - SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | 3593.698% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | -0.09% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | -0.09% |
| Arcoma AB | -1.12 Million SEK | 108965.248% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | -1017.562% |
| BICO Group AB (publ) | 927.9 Million SEK | -32.342% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | -853.416% |
| CellaVision AB (publ) | -56.94 Million SEK | 2256.58% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | 8354.352% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | 14623.59% |
| C-Rad AB (publ) | -127.6 Million SEK | 1062.382% |
| Duearity AB (publ) | 10.23 Million SEK | -11902.737% |
| Dignitana AB (publ) | 13.07 Million SEK | -9290.533% |
| Episurf Medical AB (publ) | -52.7 Million SEK | 2430.171% |
| Getinge AB (publ) | 5.4 Billion SEK | 77.293% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | 3603.258% |
| Iconovo AB (publ) | -10.75 Million SEK | 11517.59% |
| Integrum AB (publ) | -10.47 Million SEK | 11821.432% |
| Luxbright AB (publ) | -13.83 Million SEK | 8977.023% |
| Mentice AB (publ) | -49.56 Million SEK | 2577.605% |
| OssDsign AB (publ) | -162.78 Million SEK | 854.355% |
| Paxman AB (publ) | -11.41 Million SEK | 10861.546% |
| Promimic AB (publ) | -50.32 Million SEK | 2540.236% |
| Qlife Holding AB (publ) | 19.07 Million SEK | -6339.434% |
| SciBase Holding AB (publ) | -27.32 Million SEK | 4594.218% |
| ScandiDos AB (publ) | -1.53 Million SEK | 80309.014% |
| Sectra AB (publ) | -772.85 Million SEK | 258.892% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 641.27% |
| Senzime AB (publ) | -139.54 Million SEK | 980.028% |
| SpectraCure AB (publ) | -50.23 Million SEK | 2544.559% |
| Stille AB | -178.5 Million SEK | 787.94% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 672.091% |